Quality of life with cediranib in relapsed ovarian cancer: The ICON6 phase 3 randomized clinical trial. Issue 14 (24th March 2017)

• Record Type: Journal Article
• Authors: Stark, Dan P.; Cook, Adrian; Brown, Julia M.; Brundage, Michael D.; Embleton, Andrew C.; Kaplan, Richard S.; Raja, Fharat A.; Swart, Ann Marie W.; Velikova, Galina; Qian, Wendi; Ledermann, Jonathan A.
• Is Part Of: Cancer. Volume 123:Issue 14(2017)
• Page Start: 2752
• Page End: 2761
• Publication Date: 2017-03-24
• Subjects: chemotherapy -- health‐related quality of life -- ovarian cancer; Cancer -- Periodicals; Cancer -- Cytopathology -- Periodicals; 616.99405
• DOI: 10.1002/cncr.30657
• Languages: English
• ISSNs: 0008-543X

Abstract

Abstract : BACKGROUND: The ICON6 trial showed that cediranib, an oral inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, improved clinical outcomes for patients with platinum‐sensitive relapsed ovarian cancer when it was used with chemotherapy and was continued as maintenance therapy. This study describes health‐related quality of life (QOL) during the first year of treatment. METHODS: Four hundred fifty‐six women were randomly allocated to receive standard chemotherapy only, chemotherapy with concurrent cediranib, or chemotherapy with cediranib administered concurrently and continued as maintenance. Patients completed QOL questionnaires until disease progression every 3 weeks during chemotherapy and then every 6 weeks to 1 year. Patients alive with disease progression completed a QOL form 1 year after randomization. The primary QOL endpoint was the global score from the Quality of Life Questionnaire Core 30 (of the European Organization for Research and Treatment of Cancer) at 1 year, with the standard chemotherapy group compared with the concurrent‐maintenance cediranib group. RESULTS: The rate of questionnaire compliance was 90% at the baseline and 76% at 1 year and was similar across the 3 groups. The mean global QOL score at 1 year was 62.6 points for the standard chemotherapy group and 68.7 points for the concurrent‐maintenance group (+4.5; 95% confidence interval, –2.0 to 11.0; P = .18). Sensitivity analyses suggested that this finding was robust to the effect of missing data, and the improvement became statistically significant after adjustments for self‐reported diarrhea. CONCLUSIONS: The 6th study by the International Collaboration in Ovarian Neoplasm (ICON6) showed a significant improvement in progression‐free survival with cediranib as concurrent and maintenance therapy. No QOL detriment with cediranib was found 1 year after treatment was commenced. The maintenance of QOL along with prolonged cancer control suggests that cediranib has a valuable role in the treatment of relapsed ovarian cancer. Cancer 2017;123:2752‐61 . © 2017 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society . This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. Abstract : The ICON6 randomized controlled trial shows a significant progression‐free survival benefit with the use of cediranib, and this article shows no corresponding detriment to the quality of life. Prolonged cancer control, with quality of life maintained, suggests a role for cediranib in the treatment of relapsed ovarian cancer.